Leqembi® Shows Promising Results in Real-World Alzheimer’s Study with Over 75% Stability

Promising Results from LEADER Study on Leqembi®

The latest research on Leqembi®, a treatment for early Alzheimer's disease, reveals encouraging outcomes presented at the Alzheimer's Association International Conference® (AAIC®) 2026 in London. According to the new findings from the LEADER study, over 75% of the patients involved in the treatment remained stable, while nearly 7% showed signs of improvement after an average treatment period of 17 months.

The LEADER study, a real-world, multicenter retrospective analysis, focused on the effects of lecanemab (Leqembi) on patients diagnosed with early-stage Alzheimer’s disease (AD). The results indicate that 75.9% of patients maintained their initial disease stage throughout the treatment, while 6.6% improved from mild Alzheimer's dementia to mild cognitive impairment (MCI) due to Alzheimer's. These results provided vital insights into the effectiveness of Leqembi in settings outside of controlled clinical trials.

Study Design and Patient Demographics

The study included data from 432 participants who received at least seven infusions of Leqembi in diverse clinical settings across the United States. Patient characteristics indicated a mean age of 74 years, with females comprising about 55.8% of the participants. The baseline disease stage showed that 63.9% of participants had mild cognitive impairment due to Alzheimer’s, while 36.1% were in the mild dementia stage.

The average duration of Leqembi treatment was approximately 520 days, averaging out to 26 doses per patient. The primary objectives of the study were to assess treatment efficacy, safety, patient adherence, and healthcare professional insights, making it one of the most comprehensive evaluations of lecanemab to date.

Key Findings and Safety Observations

The interim analysis revealed that overall, 82.5% of participants remained stable or improved, irrespective of sex, race, ethnicity, and their APOE genotype. Further analysis indicated that among the patients who transitioned to maintenance dosing every four weeks, nearly 81% stabilized or improved.

Safety assessments aligned closely with the U.S. FDA-approved safety profile for Leqembi, with a reported 12.3% incidence of ARIA (amyloid-related imaging abnormalities)—a common occurrence for anti-amyloid treatments. Notably, most cases were asymptomatic and mild. Furthermore, the occurrence of ARIA did not significantly differ based on the use of antithrombotic therapy, reassuring many ongoing treatments.

Implications for Alzheimer’s Treatment

These findings potentially underscore the long-term benefits of continuous treatment with Leqembi for early Alzheimer’s disease, advocating for its sustained use in similar patient populations. As the landscape of Alzheimer's treatment continues to evolve, results from the LEADER study will play a crucial role in guiding clinical practices and regulatory decisions that could alleviate the burden of this debilitating disease.

The collaboration between BioArctic and Eisai ensures that innovative research continues in Alzheimer’s treatment, with Leqembi being one of the first drugs to demonstrate a significant impact on disease progression. The optimism generated by the LEADER study results shines a light on the potential for improving quality of life for many facing early Alzheimer's disease, as advocates and medical professionals push for continued support and funding for research and treatments in this area.

Future Directions

Looking toward the future, BioArctic and Eisai remain committed to advancing research and enhancing treatment options. With Leqembi currently approved in 53 countries and ongoing reviews in several others, the continuing development of therapies aimed at combating Alzheimer's will likely gain momentum, providing hope for patients and families battling this condition.

The LEADER study not only offers crucial real-world evidence of Leqembi’s efficacy but also highlights the importance of long-term treatment strategies in managing Alzheimer’s disease, encouraging further exploration and understanding of this complex illness.